



ENGOT-OV16 / NOVA



Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer

NCT01847274

Sponsor: Tesaro


ENGOT Lead: NSGO

Primary Investigators


Mirza (ENGOT); Matulonis (US)

ENGOT-OV16 / NOVA

Phase 3 Randomized Double-Blind Trial of Maintenance with Niraparib Versus Placebo in Patients with Platinum Sensitive Ovarian Cancer



Primary Endpoint	PFS in gBRCA^{mut} and non-gBRCA^{mut} cohorts (HRD positive subset followed by overall)
Key Secondary Endpoints	<ul style="list-style-type: none"> • Overall survival (OS) • Patient-reported outcomes (PRO) • Chemotherapy-free interval (CFI) • Safety and tolerability • PFS2 • Evaluation of QTc



ENGOT Group	No. of sites	Randomised gBRCA	Randomised non-gBRCA
NSGO (DK, N, SE)	9	22	52
AGO (Germany)	13	22	29
AGO (Austria)	3	3	3
BGOG (Belgium)	5	6	12
GEICO (Spain)	7	13	33
GINECO (France)	7	17	29
MaNGO & MITO (Italy)	8	13	4
NCRI (UK)	9	7	24
ISGO (Israel)	8	8	8
ENGOT TOTAL	71	111 (57%)	194 (56%)
US	39	59	95
Canada	9	21	44
Poland, Hungary	8	3	13
TOTAL	127	194	346

ENGOT-OV16 / NOVA